What are AGEs?
AGEs are metabolic byproducts that occur when sugar binds to a protein, lipid, or part of a nucleic acid. Produced by the famous Melad reaction in the food world, where glycoproteins and heat cause them to brown.

Generally speaking, food that has been cooked, baked, or fried looks delicious, and this is due to the fact that after cooking, baking, or frying, a class of brown compounds, known as AGEs, are produced by the Meladic pronouncement.

How to develop peptide-specific antibodies quickly

Many of today's junk and processed foods have AGEs.

Although the Merad reaction is known for its ability to make food delicious, the resulting chemicals can wreak all kinds of havoc on the body. They cause inflammation and oxidative damage, leading to hardening of the blood vessels, high blood pressure, kidney disease, cancer, and neurological problems.

Not only that, but once AGEs are formed, they cannot be easily detoxified. Instead, the body's ability to remove AGEs gradually decreases with age. So this provides yet another example of the age-related nature of the diseases mentioned above.
And in order to understand the specific effects of AGEs, the researchers specifically used worms, an animal that has a relatively short life cycle, to conduct the tests so that the effects behind them could be more clearly observed.

In the tests, the researchers found that the chemicals, in addition to causing disease and shortening life expectancy, also increased the worms' appetite for the same substances.

Why do AGEs whet the appetite?
To understand why worms' appetites are whetted by AGEs, the researchers purified some well-studied AGEs and found that two of them increased feeding. They further studied one of the compounds to figure out the signaling mechanism.

They showed that food intake was passively increased in mice in the presence of the glod-4 mutation, a mechanism mediated by a specific MG-H1 AGE (methylglyoxal-derived hydroimidazolone-1, a class of AGEs). Further analysis revealed that the GATA transcription factor ELT3 mediates the MG-H1 AGE through a tyramine-dependent pathway to achieve this goal.

This work identifies, for the first time, signaling pathways mediated by specific AGE molecules that enhance feeding and neurodegeneration. They also found that mutant worms that are unable to process naturally produced AGEs have lifespans that are approximately 2530% shorter. And the work is now being extended to rats, where the researchers want to study the link between AGEs and fat metabolism.

Some simple things anyone can do to lighten the burden of AGEs in the body include eating whole grains (fiber helps keep glucose levels stable), cooking with moist heat rather than drying (i.e., steaming rather than sauting or baking), and adding acids to foods as they are cooked to slow down the reactions that lead to the formation of AGEs.

Over the past two decades, much of the research into new cancer treatments and drugs has focused on genetic targets that promote cancer growth and spread by altering cellular signaling or turning off tumor suppressors. However, there is growing evidence that unique features of cancer cell metabolism may offer new opportunities for developing therapies that target tumors directly without affecting healthy cells.

Recently, researchers at Harvard Medical School published a study in Nature entitled "Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer". The study found that PDAC uses a unique metabolic pathway rarely used by normal cells to obtain and produce the nutrients it needs to survive. This pathway relies on ornithine aminotransferase (OAT), providing a new target for developing therapies specifically targeting PDAC with fewer side effects.

Best linker strategy for scFv-CH3 bispecific design

PDAC is a highly lethal malignancy with increasing incidence and poor prognosis, creating an urgent need for the development of effective therapies. Although targeting tumor metabolism has been a hot topic in cancer research for more than a decade, the plasticity of tumor metabolism and the high risk of toxicity limit this anticancer strategy.

To support tumor growth, pancreatic tumors must produce large amounts of polyamine compounds. Most cells use an arginine-dependent process to make the polyamines they need. However, the microenvironment of pancreatic tumors is typically deficient in spermidine.

In this new study, the team found in vitro and in vivo models in humans and mice that PDAC has a significant dependence on glutamine for the de novo synthesis of ornithine. This dependence is associated with arginine depletion in the PDAC tumor microenvironment and is driven by mutant KRAS, which is mutationally activated to induce the expression of OAT and polyamine synthase, leading to changes in the transcriptome and open chromatin landscape of PDAC cells.

That is, pancreatic tumors switch to the OAT pathway, which uses glutamine instead of arginine to produce polyamines, a pathway that is primarily active in the intestine of infants and fasting adults. By using the OAT pathway to produce polyamines, tumors can overcome the challenging arginine-deficient tumor microenvironment. This provides a new targettargeted inhibition of OATthat promises to inhibit tumor growth.

To test this idea, the team suppressed OAT expression by knocking out the OAT gene or using inhibitors to block OAT in cells and mouse models. Metabolic and cell growth experiments showed that both approaches significantly inhibited tumor cell growth in both cells and mouse models.

"We wanted to develop a compound that would target an enzyme used primarily by cancer cells so that it could attack tumors with fewer side effects without affecting other normal cells," according to the research team. This study found that pancreatic cancer cells use OAT to produce polyamines, a metabolite required for growth. Normal adult cells do not normally use this pathway, so OAT could be a potential therapeutic target for pancreatic cancer.

Faced with the lack of spermidine in the tumor microenvironment, cancer has found a solution to the problem by producing polyamines needed for growth through the OAT pathway, and this study shows that targeting this pathway, which cancer cells cannot bypass, is a new option for pancreatic cancer treatment with strong clinical translational value.

In the race to develop the next generation of neurotherapeutics, one unexpected player is taking center stage: the monkey.

Thats rightnon-human primates (NHPs) have become essential to cutting-edge biomedical research, especially in neurology, immunology, and vaccine development. With cerebrospinal fluid (CSF) from rhesus monkeys commanding up to $50,000 per vial and a limited global supply, primate biospecimens are now seen as biotechs version of liquid gold.

Why NHPs? The Genetic Edge
What makes NHPs so valuable in drug development? It all comes down to genetic similarity. Rhesus macaques, cynomolgus monkeys, and African green monkeys share upwards of 93% of their genome with humans. This genetic closeness translates to highly predictive pharmacokinetic and pharmacodynamic dataespecially in the brain.

How to isolate and store cynomolgus PBMCs under GMP

CSF, in particular, offers a direct window into central nervous system activity. Because it crosses the blood-brain barrier, CSF samples provide real-time insight into how experimental drugs behave once inside the brain. In fact, published studies report CSF flow rates in macaques at approximately 0.018 mL/min, making them ideal for studying neurological drug distribution.

The Supply Chain Squeeze
Despite soaring demand, supply of NHP biospecimens remains painfully constrained. Breeding cycles for monkeys can stretch 57 years, and ethical regulations have tightened globally. Meanwhile, samples like CSF have extremely narrow viability windowsoften less than 48 hours between extraction and analysisrequiring precise cold-chain logistics and processing.

Adding to the pressure, CSF is a critical resource for validating treatments for Alzheimers, Parkinsons, multiple sclerosis, and glioblastoma. Researchers are racing to evaluate biomarkers such as tau proteins and alpha-synuclein, making high-quality NHP CSF a cornerstone for translational CNS research.

Monkey Fluids in the Spotlight
Among available NHP models, rhesus macaque CSF remains the top choice for Alzheimers-related drug development. These samples are often cryopreserved at -80C and validated for PCR and western blot applications. Their consistency and compatibility with standard assays make them a preferred matrix for preclinical screening.

But rhesus monkeys arent the only stars of the show. Cynomolgus CSF has gained traction in Parkinsons disease studies, thanks to its use in spontaneous PD-like models. Meanwhile, the African green monkey is emerging as a promising model for mRNA vaccine research, offering valuable immunological and toxicological insight.

Ethics, Welfare, and Innovation
With increased use comes increased scrutiny. Ethical sourcing of NHP samples is a major concern among scientists, institutions, and regulators. Thats why responsible providers are now implementing stress-reduction collection protocols, round-the-clock veterinary monitoring, and complete traceability systems for every sample.

Some are even turning to blockchain technology to log the full history of each vialfrom animal welfare data to transport recordsensuring transparency across the research pipeline.

Where Science Meets Speed
For researchers, time is everything. In therapeutic areas like Alzheimers and rare CNS disorders, every day counts. Institutions equipped with vertically integrated NHP sourcing, in-house cryopreservation, and rapid shipping networks are proving critical in helping researchers meet urgent project deadlines without compromising quality.

Whether its a large pharmaceutical company preparing for an IND filing or a university lab validating a novel CNS biomarker, access to reliable, ethically sourced NHP biospecimens is fast becoming the deciding factor in research timelines.

Final Thoughts
Non-human primates have quietly become the linchpin of translational medicine. As neuroscience and immunotherapy push into more complex territory, NHP biospecimensespecially cerebrospinal fluidare no longer just lab supplies; theyre strategic assets. With innovation accelerating and ethical sourcing advancing, the primate gold rush is only just beginning.